Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

ocifisertib (CFI-400945)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Treadwell Therap

Drug class:

PLK4 inhibitor

Related drugs:

‹

›

No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	CFI-400945 Sensitive: B - Late Trials CFI-400945 Sensitive : B	CFI-400945 Sensitive: B - Late Trials CFI-400945 Sensitive : B
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3
PTEN deletion + ER positive	HER2 Negative Breast Cancer	PTEN deletion + ER positive	HER2 Negative Breast Cancer	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3	CFI-400945 Sensitive: C3 – Early Trials CFI-400945 Sensitive : C3
PLK4 expression	Leiomyosarcoma	PLK4 expression	Leiomyosarcoma	CFI-400945 Sensitive: D – Preclinical CFI-400945 Sensitive : D	CFI-400945 Sensitive: D – Preclinical CFI-400945 Sensitive : D
PLK4 expression	Diffuse Large B Cell Lymphoma	PLK4 expression	Diffuse Large B Cell Lymphoma	CFI-400945 Sensitive: D – Preclinical CFI-400945 Sensitive : D	CFI-400945 Sensitive: D – Preclinical CFI-400945 Sensitive : D